Loading...
01/11 03:36
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call reveals strong financial performance with significant improvements in gross margins and a reduced net loss. The strategic plan outlines ambitious growth prospects, including new product developments and market expansions. Although some uncertainty exists around partnerships and timelines, the overall sentiment is optimistic with increased revenue guidance and improved financial health. The Q&A section did not highlight any major concerns, supporting a positive outlook. Given these factors, a positive stock price movement is likely over the next two weeks.
Product Revenue (Q4 FY 2025) $2.7 million, a 907% increase year-over-year. This growth was driven by the expansion of commercialization efforts for the OneRF brain ablation system distributed by Zimmer Biomet.
Product Revenue (Full FY 2025) $9.1 million, a 163% increase year-over-year. The increase was attributed to record product sales growth.
License Revenue (FY 2025) $3 million, compared to no license revenue in FY 2024. This revenue was derived from the expanded exclusive distribution agreement with Zimmer Biomet.
Product Gross Margins (Q4 FY 2025) 55.8%, compared to 51.8% in Q4 FY 2024. The improvement was due to the expansion of commercialization efforts.
Product Gross Margins (Full FY 2025) 56.5%, compared to 31.3% in FY 2024. The significant improvement was attributed to increased product sales and operational efficiencies.
Operating Expenses (Q4 FY 2025) $2.9 million, a 2% decrease year-over-year. This reduction was achieved despite increased commercialization efforts.
Operating Expenses (Full FY 2025) $12.4 million, a 5% decrease year-over-year. The decrease was due to cost management and operational efficiencies.
Net Loss (Q4 FY 2025) $1.6 million or $0.03 per share, a 52% improvement year-over-year. This improvement was driven by increased revenue and reduced operating expenses.
Net Loss (Full FY 2025) $3.6 million or $0.09 per share, a 71% improvement year-over-year. The improvement was due to increased revenue, improved gross margins, and reduced operating expenses.
Cash and Cash Equivalents (as of September 30, 2025) $6.6 million, compared to $1.5 million as of September 30, 2024. The increase was due to an $8.2 million capital raise.
Working Capital (as of September 30, 2025) $7.9 million, compared to $2.4 million as of September 30, 2024. The improvement was driven by increased cash reserves and no outstanding debt.
FDA 510(k) clearance for OneRF trigeminal nerve ablation system: Received clearance for treating facial pain, with successful initial patient treatments and positive outcomes.
Development of spinal cord stimulation electrode: Advanced development for lower back pain treatment.
New product development for basivertebral nerve ablation: Initiated program for lower back pain treatment.
Drug delivery devices: Reported first preclinical sales to a large pharmaceutical company and initiated development for glioblastoma and other neurological disorders.
International commercial expansion: Initiated ISO 13485 certification process to support global sales.
Zimmer Biomet partnership: Expanded exclusive distribution agreement, contributing to significant revenue growth.
Revenue growth: Achieved 163% annual growth in product sales to $9.1 million and 907% quarterly growth to $2.7 million.
Improved gross margins: Increased product gross margins to 56.5% for the year.
Cost management: Reduced operating expenses by 5% for the year.
Capital raise: Strengthened balance sheet with $8.2 million capital raise.
Patent portfolio expansion: Granted new U.S. and European patents, bringing total to 17 issued and pending patents.
Pain management platform: Developing two technologies for lower back pain, including percutaneous paddle electrode and basivertebral nerve ablation system.
Drug delivery partnerships: Exploring partnerships for gene therapy, cell therapy, and glioblastoma drug delivery.
NASDAQ compliance risk: The company has been granted a 180-day extension until May 4, 2026, to regain compliance with NASDAQ's minimum bid price rule for continued listing. Failure to meet this requirement could result in delisting from the NASDAQ Capital Market.
Regulatory approval dependency: The company's future growth in drug delivery and other platforms is dependent on gaining FDA clearance, which introduces regulatory risk.
Strategic partnership uncertainty: The company is in early discussions with potential partners for its pain management and drug delivery technologies. The lack of finalized agreements poses a risk to the commercialization and scaling of these platforms.
Market adoption challenges: While the company has reported initial success with its OneRF trigeminal nerve ablation system, broader market adoption and clinical validation are still in progress, which could impact revenue growth.
Supply chain and production risks: The company is expanding its product portfolio and entering new markets, which may strain its supply chain and production capabilities.
Economic and financial risks: Although the company has improved its financial position, it remains dependent on achieving key milestones to extend funding beyond fiscal 2026.
Financial Guidance for Fiscal Year 2026: The company plans to provide financial guidance for fiscal year 2026 once it receives a final forecast from its distribution partner, Zimmer Biomet.
Drug Delivery Program: The company aims to be commercially ready with its preclinical drug delivery offerings in 2026 and develop a pathway to gain FDA clearance. This program targets brain-related neurological disorders such as glioblastomas, epilepsy, and Parkinson's disease.
Pain Management Platform: Two active programs are in development for treating lower back pain: a percutaneously placed paddle electrode and a basivertebral nerve ablation system. Chronic animal studies for the paddle electrode are expected to finish in fiscal Q2 2026, with additional long-term studies to follow. The basivertebral nerve ablation system will undergo animal studies and continued R&D testing.
OneRF Trigeminal Nerve Ablation System: The company plans to continue limited commercial launches and perform additional cases to obtain post-market clinical performance information. Discussions are ongoing with a strategic partner to potentially license this technology.
OneRF Brain Ablation System: The company expects increased revenue from this system, which is marketed by Zimmer Biomet. Clinical outcomes have been positive, and the product is being released to additional sites. A registry is being established to gather performance data.
The selected topic was not discussed during the call.
The earnings call reveals strong financial performance with significant improvements in gross margins and a reduced net loss. The strategic plan outlines ambitious growth prospects, including new product developments and market expansions. Although some uncertainty exists around partnerships and timelines, the overall sentiment is optimistic with increased revenue guidance and improved financial health. The Q&A section did not highlight any major concerns, supporting a positive outlook. Given these factors, a positive stock price movement is likely over the next two weeks.
The earnings call reveals strong financial performance, with significant revenue and margin growth, reduced expenses, and improved net loss. The partnership with Zimmer Biomet and international expansion plans are promising. Despite management's cautious stance on 2026 guidance, the optimistic FY 2025 outlook and strategic partnerships suggest a strong positive sentiment. The Q&A session highlights potential growth areas and addresses concerns, further solidifying the positive outlook. Given the context and potential for expansion, a strong positive stock price movement is expected, likely exceeding 8%.
The earnings call highlights strong financial performance, including record revenue and gross margins, a significant partnership with Zimmer Biomet, and improved net loss figures. The Q&A reveals reliance on Zimmer for revenue and some uncertainty regarding non-Zimmer revenue, but overall sentiment remains positive due to the partnership's potential and no debt. The capital raise ensures financial stability, and the addition of a Chief Medical Advisor indicates strategic growth. Despite some risks and uncertainties, the overall outlook is positive, likely resulting in a stock price increase of 2% to 8%.
NeuroOne's earnings report highlights strong financial performance with record product sales and gross margins, along with a significant partnership expansion with Zimmer Biomet. Despite some uncertainties in the Q&A, the company's improved financial health, no debt, and guidance of being fully funded through fiscal 2026 are positive indicators. The competitive pressures and supply chain challenges are present but are outweighed by the strategic partnership and financial improvements. The stock is likely to see a positive reaction over the next two weeks.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
